Company / Net Income
CHINA PHARMA HOLDINGS, INC. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$3.2M
FY2025
5-year range
-$4.0M / -$2.9M
FY2021-FY2025
Trend
-3.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 10 years, ranging from -$21M in FY2020 to -$3M in FY2021.
Based on SEC 10-K filings.
-$3M in FY2025.
Declined from -$3M to -$3M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income decreased 3.5% year-over-year.
- Peak net income was recorded in FY2021.
- Lowest net income in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.2M | -3.5% |
| FY2024 | -$3.1M | +0.0% |
| FY2023 | -$3.1M | +22.5% |
| FY2022 | -$4.0M | -38.6% |
| FY2021 | -$2.9M | +86.2% |
| FY2020 | -$20.7M | -92.6% |
| FY2019 | -$10.8M | +44.2% |
| FY2018 | -$19.3M | -109.9% |
| FY2017 | -$9.2M | +40.4% |
| FY2016 | -$15.4M | +61.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026